Tatsuya Ito

Tatsuya Ito

Auto-generated profile, based on publicly available information

Tatsuya Ito

Department of Head and Neck Surgery, National Cancer Center Japan, Chuo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

6 October 2026 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
TITatsuya Ito
Tatsuya Ito
KEKohtaro Eguchi
Kohtaro Eguchi
MKMitsuhiko Katoh
Mitsuhiko Katoh
GOGo Omura
Go Omura
CFChihiro Fushimi
Chihiro Fushimi
SYSeiichi Yoshimoto
Seiichi Yoshimoto
Immune checkpoint inhibitors (ICIs) are increasingly incorporated into perioperative cancer treatment, raising challenges in distinguishing immune-related adverse events (irAEs) from postoperative complications. We report a case of postoperative immune-related colitis following head and neck reconstructive surgery in a patient receiving long-term nivolumab. A man receiving nivolumab for gastric cancer, who was maintained on prednisolone for prior immune-related myositis, underwent subtotal glossectomy for advanced tongue cancer. Despite perioperative steroid coverage, he developed grade 3 diarrhoea on postoperative day 4. After infectious causes were excluded and CT revealed diffuse colitis, empirical corticosteroid therapy was initiated, with rapid symptom resolution; colonoscopy and biopsy supported a diagnosis of immune-related colitis. This case illustrates that irAE colitis should remain in the differential diagnosis of postoperative diarrhoea in patients with prior ICI exposure. As perioperative use of ICIs expands, clinicians should maintain a high index of suspicion for irAEs in patients presenting with postoperative diarrhoea.